257 related articles for article (PubMed ID: 30987833)
1. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
5. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
[TBL] [Abstract][Full Text] [Related]
6. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
7. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
8. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
9. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
10. HSP60 predicts survival in advanced serous ovarian cancer.
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
[TBL] [Abstract][Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
12. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
14. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
15. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
16. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
17. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
18. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
19. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
20. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D
Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
